Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus standard treatment in AChR antibody-positive generalized myasthenia gravis
ChiCTR2400083807Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ocrelizumab in myasthenia gravis (MG) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Change in QMG score from baseline to Week 24, Change in MG-ADL score from baseline to Week 24 and 1 more. Started May 2024; status: completed.
02
Drugs
ocrelizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2400083807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083807.